Category: Let’s Interview Series

Megakaryon is aiming for mass production of the first global iPSC (induced Pluripotent Stem Cell)-derived platelet product for allogeneic use. Learn more about the Kyoto-based organization in this installment of our Let’s Interview Series.

Venture Valuation (VV) interviewed Dr. AKAMATSU Kenichi, CEO, and Mr. AYABE Tsuyoshi, COO & CFO.

Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?

Sound Wave Innovation is developing proprietary LIPUS (Low-Intensity Pulsed Ultrasound) brain therapy, focusing on early-stage Alzheimer’s disease. Learn more about the Tokyo-based organization in this installment of our Let’s Interview Series.

Venture Valuation (VV) interviewed Dr. SHIMOKAWA Hiroaki, Founder & CMO, KATO Hajime, CEO, and MANO Takamitsu, Corporate Director.

Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?

Pixie Dust Technologies invented a new audio method with gamma wave sound to prevent or even improve Alzheimer’s disease. Learn more about the Tokyo-based organization in this installment of our Let’s Interview Series.

Venture Valuation (VV) interviewed TSUJI Mitsutaka, General Manager, and NAGATANI Yoshiki, PhD, Senior Engineer.

Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?

Rebirthel are preparing the first clinical trial conducted in humans for acute myeloid leukemia to evaluate safety and efficacy. Learn more about the Kyoto-based organization in this installment of our Let’s Interview Series.

Venture Valuation (VV) interviewed President and CEO, Mr. Kajikawa Masunori.

Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?

Human Life Cord specialize in allogeneic cell therapy, applying umbilical cord derived mesenchymal stromal cells (MSCs) that are able to differentiate into a variety of cell types. Learn more about the Tokyo-based organization in this installment of our Let’s Interview Series.

Venture Valuation (VV) interviewed President and CEO, Mr. Harata Masamitsu.

Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?

Sonire Therapeutics has commenced a randomized Phase 2 study for the treatment of unresectable pancreatic cancer with their next-generation High-Intensity Focused Ultrasound therapy system. Learn more about the Tokyo-based organization in this installment of our Let’s Interview Series.

Venture Valuation (VV) interviewed President and CEO, Mr. Satoh Toru.

Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?

J-Pharma is a frontrunner in developing inhibitors of L-type amino acid transporter for treating advanced refractory cancers and autoimmune diseases. Learn more about the Yokohama-based organization in this installment of our Let’s Interview Series.

Venture Valuation (VV) interviewed President and CEO, Mr. Max Yoshitake.

Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?

Aipore is developing AI-enabled solid-state nanospore sensor technology that can detect SARS-CoV2 coronavirus in saliva specimens within 5 minutes. Learn more about the Tokyo-based organization in this installment of our Let’s Interview Series.

Venture Valuation (VV) interviewed Founder and CEO, Mr. Naono Norihiko.

Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?

Varinos commercialized the world’s first highly accurate endometrial microbiome testing service by applying next-generation sequencing. Learn more about the Tokyo-based organization in this installment of our Let’s Interview Series.

Venture Valuation (VV) interviewed Founder and CEO, Dr. Sakuraba Yoshiyuki.

Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?

Founded in 2020 and winners of the XY Factor competition at Biotechgate Digital Partnering February 2022, POLARISqb have built the first ever drug discovery platform using a quantum computer – Tachyon™ – to shorten the years-long preclinical drug design and optimization process to just a few months.

Venture Valuation (VV) interviewed CEO and co-founder, Shahar Keinan, Ph.D.

Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?